Isoniazid preventive treatment: predictors of adverse events and treatment completion
BACKGROUND: A recent report on the fatal side effects of isoniazid preventive therapy (IPT) from the United States has re-ignited discussion on the safety of this intervention.
OBJECTIVE: To evaluate IPT feasibility, treatment completion and adverse events (AE) and their determinants under field conditions.
METHODS: Data from consecutive subjects undergoing IPT at the VMI were recorded in an electronic database from 1992 to 2009. Logistic regression analysis was performed to detect completion and AE determinants.
RESULTS: A total of 11 963 patients were included in the study. AE (odds ratio [OR] 2.70, 95%CI 2.22–3.28) and human immunodeficiency virus positive status (OR 5.20, 95%CI 2.10–12.93) were the main determinants of treatment interruption among Italians, while social weakness (no housing/job; OR 2.88, 95%CI 2.43–3.42), AEs (OR 1.33, 95%CI 1.15–1.53, 2.22–3.28) and screening in undocumented subjects (OR 1.20, 95%CI 1.01–1.44) prevailed among foreigners. Age was the main determinant of transaminase increase (OR 1.03, 95%CI 1.03–1.04), as were AEs of the gastrointestinal (OR 1.02, 95%CI 1.02–1.03), central nervous (OR 1.02, 95%CI 1.02–1.05) and peripheral nervous systems (OR 1.04, 95%CI 1.02–1.05).
CONCLUSION: This analysis demonstrates the feasibility and safety of IPT, with determinants of interruption and AEs being predictable and addressable.
Document Type: Research Article
Affiliations: 1: Regional TB Reference Centre, Villa Marelli Institute, Niguarda Ca'Granda Hospital, Milan, Italy 2: Section of Occupational Medicine, Occupational and Environmental Respiratory Diseases and Toxicology, University of Perugia, Perugia, Italy 3: Section of Respiratory Diseases, S Maria Hospital, University of Perugia, Terni, Italy 4: Section of Respiratory Diseases, S Maria Hospital, University of Perugia, Terni, Italy; Respiratory Medicine Unit, Department of Medicine, Karolinska Institutet and Lung Allergi Kliniken, Karolinska University Hospital, Solna, Sweden 5: Stop TB Department, World Health Organization, Geneva, Switzerland
Publication date: July 1, 2013
The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.
The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- Ingenta Connect is not responsible for the content or availability of external websites